Document is current
Any future updates will be listed below
-
Authors
Seano, Giorgio
Nia, Hadi T. https://orcid.org/0000-0003-1970-9901
Emblem, Kyrre E.
Datta, Meenal
Ren, Jun https://orcid.org/0000-0002-6358-0765
Krishnan, Shanmugarajan
Kloepper, Jonas
Pinho, Marco C.
Ho, William W.
Ghosh, Mitrajit
Askoxylakis, Vasileios
Ferraro, Gino B.
Riedemann, Lars
Gerstner, Elizabeth R.
Batchelor, Tracy T.
Wen, Patrick Y.
Lin, Nancy U.
Grodzinsky, Alan J.
Fukumura, Dai
Huang, Peigen
Baish, James W.
Padera, Timothy P. https://orcid.org/0000-0002-3453-9384
Munn, Lance L.
Jain, Rakesh K. https://orcid.org/0000-0001-7571-3548
- License Information
-
More Information
Article History
Received: 22 December 2017
Accepted: 25 November 2018
First Online: 7 January 2019
Change Date: 30 January 2019
Change Type: Update
Change Details: In the version of this Article originally published, Supplementary Video 2 was incorrectly linked to Supplementary Video 3, and Supplementary Video 3 was incorrectly linked to Supplementary Video 2. The files have now been replaced to rectify this.
Competing interests
: R.K.J. received an honorarium from AMGEN and consultant fees from Pfizer, Ophthotech, Merck, SPARC, SynDevRx and XTuit. R.K.J. owns equity in Enlight, Ophthotech and SynDevRx, and serves on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, the Tekla Healthcare Opportunities Fund and the Tekla World Healthcare Fund. No reagents or funding from these companies was used in these studies. K.E.E. has intellectual properties with NordicNeuroLab AS, Bergen, Norway.
